<DOC>
	<DOCNO>NCT01609023</DOCNO>
	<brief_summary>This observational study evaluate safety efficacy MabThera/Rituxan ( rituximab ) combination chemotherapy 1st 2nd line treatment patient CD20-positive C-cell chronic lymphocytic leukaemia . Data collect eligible patient receive MabThera/Rituxan accord Summary Product Characteristics 6 month treatment .</brief_summary>
	<brief_title>An Observational Study MabThera/Rituxan ( Rituximab ) Combination With Chemotherapy Patients With CD20-Positive B-Cell Chronic Lymphocytic Leukaemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Patients CD20positive Bcell chronic lymphocytic leukaemia eligible 1st line 2nd line therapy accord approve summary product characteristic ( SPC ) Contraindications MabThera/Rituxan therapy accord approve SPC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>